fda declaratory order semaglutide shortage resolved february 21 2025 GLP-1 Saga Continues: Ends the Tirzepatide The Industrialization of Exceptions: When

Abstract Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk

Effects typically appear within 46 weeks

As of May 2026, FDA has also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, after stating that it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances when FDA-approved versions are available

Harth G, Zamecnik PC, Tang JY, Tabatadze D, Horwitz MA: Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication